Advanced Micro Devices, Inc. vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines Advanced Micro Devices, Inc. and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Advanced Micro Devices, Inc. on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Advanced Micro Devices, Inc. and Cardinal Health, Inc. is widest.

On the headline numbers, Advanced Micro Devices, Inc. reports annual revenue of $34.6B against $254.2B for Cardinal Health, Inc., while their respective market capitalizations stand at $999.5B and $56.0B. Both Advanced Micro Devices, Inc. and Cardinal Health, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Advanced Micro Devices, Inc.: Advanced Micro Devices spent most of its first four decades as Intel's smaller x86 rival, competitive in some generations and close to failure in others. It moved its fabs into GlobalFoundries in 2009, and after Lisa Su became CEO in October 2014 it concentrated its engineering budget on one clean-sheet CPU core, Zen. Ryzen and EPYC arrived in 2017, and the Xilinx and Pensando deals in 2022 widened the portfolio past CPUs and graphics. AMD now designs server and desktop processors, Radeon graphics, Instinct AI accelerators, and adaptive SoCs, and supplies the semi-custom chips inside the PlayStation 5 and Xbox Series consoles.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Advanced Micro Devices, Inc. and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Advanced Micro Devices, Inc. and Cardinal Health, Inc..

Advanced Micro Devices, Inc. business model: Advanced Micro Devices runs a fabless semiconductor model. It designs CPUs, GPUs, AI accelerators, FPGAs, and adaptive SoCs, and contracts the wafer manufacturing to outside foundries, primarily TSMC. That structure keeps leading-edge fabrication off AMD's balance sheet and makes engineering its largest investment: research and development cost $8.1B in FY2025, about 23% of revenue. Revenue comes from three reportable segments. Data Center, $16.6B in FY2025, covers EPYC server CPUs, Instinct AI accelerators, Pensando DPUs, AI network interface cards, and adaptive SoCs sold to cloud providers, enterprises, and HPC customers. Client and Gaming, $14.6B, covers Ryzen desktop and notebook processors, chipsets, Radeon discrete graphics, and the semi-custom SoCs inside PlayStation and Xbox consoles; within it Client was $10.6B and Gaming $3.9B. Embedded, $3.5B, covers the Xilinx-derived FPGA, system-on-module, and adaptive SoC lines sold into telecom, aerospace, defense, automotive, and industrial equipment. The design lever is chiplets: AMD splits a processor into several smaller dies joined by Infinity Fabric, which raises usable yield and lets it mix process nodes inside one package.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Advanced Micro Devices, Inc. stack up against those of Cardinal Health, Inc..

Advanced Micro Devices, Inc. competitive advantage: AMD's advantage is design and packaging execution without fab ownership. Because it buys capacity from TSMC instead of running leading-edge fabs, it can move to a newer process node as soon as the foundry has one in volume. Its chiplet approach assembles a processor from smaller dies linked by Infinity Fabric, which improves usable yield and makes high core-count parts cheaper to build than a single large die. Zen-based EPYC and Ryzen processors converted that into server and client share gains against Intel, and 3D V-Cache gives the Ryzen X3D desktop parts a cache advantage in games.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Future prospects matter as much as current results. The growth strategies below explain how Advanced Micro Devices, Inc. and Cardinal Health, Inc. each plan to expand from here.

Advanced Micro Devices, Inc. growth strategy: AMD's growth plan centers on data center AI, funded by $8.1B of research and development in FY2025. It has bought capability rather than waiting to build it: Xilinx in February 2022 for FPGAs and adaptive computing, a deal announced in October 2020 at about $35B in stock and worth roughly $49B at close; Pensando in May 2022 for DPUs at about $1.9B; Silo AI in August 2024 for AI software engineering at about $665M; and ZT Systems in March 2025 for rack-scale systems design. The aim is to sell complete AI racks that combine EPYC CPUs, Instinct accelerators, AI networking, and ROCm software instead of individual chips, while Ryzen and Radeon keep funding the effort.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

A closer look at the financial trajectory of Advanced Micro Devices, Inc. and Cardinal Health, Inc. rounds out the comparison.

Advanced Micro Devices, Inc.: AMD's decade is a turnaround with a paper trail. Revenue fell to $4.0B in 2015 and the company lost $660M; its market value ended that year near $2.3B. Zen-based Ryzen and EPYC parts, and Intel's process delays, shifted the mix toward servers and then AI accelerators. FY2025 revenue was $34.6B, up 34% from $25.8B, with net income of $4.3B, a 50% gross margin, $8.1B of research and development spending, and $4.1B of marketing, general and administrative expense. Cash, cash equivalents, and short-term investments rose to $10.6B from $5.1B a year earlier, against $3.3B of total debt principal. The result also absorbed about $440M of net inventory and related charges tied to US export controls on Instinct MI308 products.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.